EP2565206A3 - Purification d'anticorps par chromatographie à échange de cations - Google Patents
Purification d'anticorps par chromatographie à échange de cations Download PDFInfo
- Publication number
- EP2565206A3 EP2565206A3 EP12189190.7A EP12189190A EP2565206A3 EP 2565206 A3 EP2565206 A3 EP 2565206A3 EP 12189190 A EP12189190 A EP 12189190A EP 2565206 A3 EP2565206 A3 EP 2565206A3
- Authority
- EP
- European Patent Office
- Prior art keywords
- cation exchange
- exchange chromatography
- antibody purification
- antibody
- eluting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000005277 cation exchange chromatography Methods 0.000 title abstract 2
- 238000011091 antibody purification Methods 0.000 title 1
- 239000000356 contaminant Substances 0.000 abstract 1
- 239000012149 elution buffer Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000005406 washing Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SI200831634A SI2565206T1 (sl) | 2007-10-30 | 2008-10-29 | Čiščenje protitelesa s kationsko izmenjevalno kromatografijo |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98382507P | 2007-10-30 | 2007-10-30 | |
EP08844379.1A EP2215117B2 (fr) | 2007-10-30 | 2008-10-29 | Purification d'un anticorps par chromatographie à échange de cations |
Related Parent Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP08844379.1 Division | 2008-10-29 | ||
EP08844379.1A Division-Into EP2215117B2 (fr) | 2007-10-30 | 2008-10-29 | Purification d'un anticorps par chromatographie à échange de cations |
EP08844379.1A Division EP2215117B2 (fr) | 2007-10-30 | 2008-10-29 | Purification d'un anticorps par chromatographie à échange de cations |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2565206A2 EP2565206A2 (fr) | 2013-03-06 |
EP2565206A3 true EP2565206A3 (fr) | 2013-11-06 |
EP2565206B1 EP2565206B1 (fr) | 2016-03-30 |
Family
ID=40262967
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18151178.3A Withdrawn EP3441402A1 (fr) | 2007-10-30 | 2008-10-29 | Purification d'anticorps par chromatographie à échange de cations |
EP14189095.4A Active EP2840090B1 (fr) | 2007-10-30 | 2008-10-29 | Purification d'un anticorps par chromatographie à échange de cations |
EP12189190.7A Active EP2565206B1 (fr) | 2007-10-30 | 2008-10-29 | Purification d'anticorps par chromatographie à échange de cations |
EP08844379.1A Active EP2215117B2 (fr) | 2007-10-30 | 2008-10-29 | Purification d'un anticorps par chromatographie à échange de cations |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18151178.3A Withdrawn EP3441402A1 (fr) | 2007-10-30 | 2008-10-29 | Purification d'anticorps par chromatographie à échange de cations |
EP14189095.4A Active EP2840090B1 (fr) | 2007-10-30 | 2008-10-29 | Purification d'un anticorps par chromatographie à échange de cations |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP08844379.1A Active EP2215117B2 (fr) | 2007-10-30 | 2008-10-29 | Purification d'un anticorps par chromatographie à échange de cations |
Country Status (32)
Country | Link |
---|---|
US (3) | US20090148435A1 (fr) |
EP (4) | EP3441402A1 (fr) |
JP (5) | JP5237382B2 (fr) |
KR (3) | KR101241486B1 (fr) |
CN (3) | CN103554215B (fr) |
AR (2) | AR069097A1 (fr) |
AU (1) | AU2008318865B2 (fr) |
BR (1) | BRPI0817182A2 (fr) |
CA (1) | CA2703279C (fr) |
CL (1) | CL2008003218A1 (fr) |
CO (1) | CO6280422A2 (fr) |
CY (1) | CY1116129T1 (fr) |
DK (3) | DK2565206T3 (fr) |
ES (3) | ES2533266T5 (fr) |
HK (4) | HK1182401A1 (fr) |
HR (2) | HRP20150282T4 (fr) |
HU (3) | HUE027668T2 (fr) |
IL (4) | IL205310A0 (fr) |
ME (1) | ME02101B (fr) |
MX (1) | MX2010004740A (fr) |
NZ (1) | NZ584839A (fr) |
PE (1) | PE20091434A1 (fr) |
PH (1) | PH12013501128A1 (fr) |
PL (3) | PL2840090T3 (fr) |
PT (1) | PT2215117E (fr) |
RS (1) | RS53850B2 (fr) |
RU (1) | RU2498991C2 (fr) |
SG (2) | SG10201401690XA (fr) |
SI (3) | SI2565206T1 (fr) |
TW (2) | TWI554517B (fr) |
WO (1) | WO2009058812A1 (fr) |
ZA (2) | ZA201002850B (fr) |
Families Citing this family (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TR201809892T4 (tr) | 2003-11-05 | 2018-07-23 | Roche Glycart Ag | Fc reseptörüne bağlanma afinitesi ve artırılmış efektör fonksiyonu bulunan antijen bağlayan moleküller. |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
PL1846030T3 (pl) * | 2005-01-21 | 2019-05-31 | Genentech Inc | Ustalone dawkowanie przeciwciał her |
UA95902C2 (ru) | 2005-02-23 | 2011-09-26 | Дженентек, Инк. | Способ увеличения времени развития заболевания или выживаемости у раковых пациентов |
WO2008033517A2 (fr) | 2006-09-13 | 2008-03-20 | Abbott Laboratories | Améliorations à la culture de cellules |
US8911964B2 (en) | 2006-09-13 | 2014-12-16 | Abbvie Inc. | Fed-batch method of making human anti-TNF-alpha antibody |
NZ578824A (en) | 2007-03-02 | 2012-03-30 | Genentech Inc | Predicting response to a her dimerisation inhibitor based on low her3 expression |
PL2840090T3 (pl) * | 2007-10-30 | 2018-07-31 | Genentech, Inc. | Oczyszczanie przeciwciał za pomocą chromatografii kationowymiennej |
TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至her2結構域ii之抗體及其酸性變異體的組合物 |
BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
AR073295A1 (es) | 2008-09-16 | 2010-10-28 | Genentech Inc | Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion. |
US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
EP2921501A1 (fr) | 2008-10-20 | 2015-09-23 | Abbvie Inc. | Isolement et purification d'anticorps par chromatographie d'affinité de la protéine A |
CN104974251A (zh) * | 2008-10-20 | 2015-10-14 | Abbvie公司 | 在抗体纯化过程中的病毒灭活 |
AR078161A1 (es) * | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
WO2011037983A1 (fr) * | 2009-09-23 | 2011-03-31 | Medarex, Inc. | Chromatographie par échange de cations |
AR080794A1 (es) * | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
WO2011123507A1 (fr) | 2010-03-30 | 2011-10-06 | Centocor Ortho Biotech Inc. | Anticorps humanisés de il-25 |
HUE037227T2 (hu) | 2010-05-14 | 2018-08-28 | Univ Oregon Health & Science | Rekombináns HCMV és RHCMV vektorok és alkalmazásuk |
SG10201710439UA (en) * | 2010-05-25 | 2018-01-30 | Genentech Inc | Methods of purifying polypeptides |
GB201012603D0 (en) | 2010-07-27 | 2010-09-08 | Ucb Pharma Sa | Protein purification |
MX357821B (es) * | 2010-12-21 | 2018-07-25 | Hoffmann La Roche | Preparación de anticuerpo enriquecida con isoforma y método para obtenerla. |
CN107915769A (zh) * | 2011-03-29 | 2018-04-17 | 葛兰素史密斯克莱有限责任公司 | 用于蛋白纯化的缓冲液体系 |
US20140107321A1 (en) * | 2011-05-26 | 2014-04-17 | Dr. Reddy's Laboratories Limited | Purification of antibodies |
HUE037408T2 (hu) | 2011-06-10 | 2018-08-28 | Univ Oregon Health & Science | CMV glikoproteinek és rekombináns vektorok |
WO2013054250A1 (fr) * | 2011-10-10 | 2013-04-18 | Dr Reddy's Laboratories Limited | Procédé de purification |
LT2766040T (lt) | 2011-10-14 | 2019-08-12 | F. Hoffmann-La Roche Ag | Pertuzumabas, trastuzumabas, docetakselis ir karboplatina, skirti ankstyvos stadijos krūties vėžiui gydyti |
RU2478646C1 (ru) * | 2011-11-28 | 2013-04-10 | Федеральное государственное бюджетное учреждение науки Институт молекулярной биологии им.В.А.Энгельгардта Российской академии наук (ИМБ РАН) | Способ получения высокоаффинных поликлональных антител |
BR112014015101A8 (pt) | 2011-12-22 | 2021-06-08 | Genentech Inc | métodos para intensificar eficiência de etapas de cromatografia a jusante para purificação de anticorpos |
EP3495387B1 (fr) | 2012-07-13 | 2021-09-01 | Roche Glycart AG | Anticorps bispécifiques anti-vegf/anti-ang-2 et leur utilisation dans le traitement des maladies vasculaires oculaires |
US20150218208A1 (en) * | 2012-08-27 | 2015-08-06 | Asahi Kasei Medical Co., Ltd. | Method for purifying antibody by temperature-responsive chromatography |
CN103217499B (zh) * | 2013-01-15 | 2015-12-02 | 珠海市丽珠单抗生物技术有限公司 | 一种测定免疫球蛋白电荷异构体的糖基化和末端修饰情况的方法 |
RU2768003C2 (ru) | 2013-03-08 | 2022-03-22 | Джензим Корпорейшн | Интегрированное непрерывное производство терапевтических белковых лекарственных веществ |
UY35517A (es) * | 2013-04-04 | 2014-10-31 | Mabxience S A | Un procedimiento para aumentar la formación de ácido piroglutamico de una proteína |
MX368259B (es) | 2013-04-16 | 2019-09-25 | Genentech Inc | Variantes de pertuzumab y su evaluacion. |
US10351592B2 (en) | 2013-10-30 | 2019-07-16 | Celltrion, Inc. | Method for separating antibody isoforms using cation exchange chromatography |
CN104628846B (zh) * | 2013-11-06 | 2019-12-06 | 三生国健药业(上海)股份有限公司 | 重组蛋白质的纯化方法 |
SG10201710475WA (en) * | 2013-11-25 | 2018-01-30 | Seattle Genetics Inc | Preparing antibodies from cho cell cultures for conjugation |
TWI671312B (zh) | 2014-01-17 | 2019-09-11 | 美商健臻公司 | 無菌層析法及製法 |
TWI709569B (zh) | 2014-01-17 | 2020-11-11 | 美商健臻公司 | 無菌層析樹脂及其用於製造方法的用途 |
JP6609561B2 (ja) * | 2014-02-04 | 2019-11-20 | バイオジェン・エムエイ・インコーポレイテッド | 翻訳後修飾を濃縮するための、フロースルーモードにおける陽イオン交換クロマトグラフィーの使用 |
HUE048782T2 (hu) | 2014-03-10 | 2020-08-28 | Richter Gedeon Nyrt | Immunoglobulin tisztítása elõtisztítási lépések alkalmazásával |
CN105017418B (zh) * | 2014-03-27 | 2021-02-23 | 上海药明康德新药开发有限公司 | 单克隆抗体纯化工艺方法 |
AU2015249633B2 (en) | 2014-04-25 | 2020-10-15 | Genentech, Inc. | Methods of treating early breast cancer with Trastuzumab-MCC-DM1 and Pertuzumab |
US10428118B2 (en) | 2014-07-16 | 2019-10-01 | Oregon Health & Science University | Human cytomegalovirus comprising exogenous antigens |
CN105315369B (zh) * | 2014-07-25 | 2020-03-13 | 山东博安生物技术有限公司 | 利用阳离子交换层析纯化蛋白质 |
CA2978095C (fr) * | 2015-03-13 | 2022-02-15 | Bristol-Myers Squibb Company | Utilisation de lavages alcalins durant une chromatographie pour eliminer les impuretes |
WO2016196373A2 (fr) | 2015-05-30 | 2016-12-08 | Genentech, Inc. | Procédés de traitement de cancer du sein métastatique her2 positif |
KR101657690B1 (ko) * | 2015-06-05 | 2016-09-19 | 주식회사 녹십자홀딩스 | 혈장 유래 b형 간염 사람 면역글로불린 제제의 제조방법 |
WO2017087280A1 (fr) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Procédés de traitement d'un cancer positif her2 |
CN116926128A (zh) | 2015-11-20 | 2023-10-24 | 俄勒冈健康与科学大学 | 包含微小rna识别元件的cmv载体 |
GB201600512D0 (en) * | 2016-01-12 | 2016-02-24 | Univ York | Recombinant protein production |
MA44873A (fr) | 2016-04-15 | 2019-03-13 | Univ Pennsylvania | Composition pour le traitement de la dégénérescence maculaire liée a l'âge exsudative |
US10654922B2 (en) * | 2016-05-13 | 2020-05-19 | Askgene Pharma Inc. | Angiopoietin 2, VEGF dual antagonists |
KR20220158870A (ko) * | 2016-07-15 | 2022-12-01 | 에프. 호프만-라 로슈 아게 | Peg화 에리트로포이에틴을 정제하기 위한 방법 |
CN106222222B (zh) * | 2016-08-08 | 2019-10-29 | 湖北医药学院 | 一种重组人白血病抑制因子的制备方法 |
WO2018045587A1 (fr) * | 2016-09-12 | 2018-03-15 | 广东东阳光药业有限公司 | Procédé de purification d'anticorps monoclonal de type anti-vegf |
CN106380519B (zh) * | 2016-10-17 | 2019-11-01 | 深圳万乐药业有限公司 | 一种单克隆抗体的纯化方法 |
CN110036112B (zh) | 2016-10-18 | 2024-05-10 | 俄勒冈健康与科学大学 | 引发受主要组织相容性复合体e分子限制的t细胞的巨细胞病毒载体 |
US11021530B2 (en) * | 2016-10-31 | 2021-06-01 | Hexal Ag | Antibody preparation |
AU2017387909A1 (en) | 2016-12-28 | 2019-06-27 | Genentech, Inc. | Treatment of advanced HER2 expressing cancer |
CR20190376A (es) | 2017-01-17 | 2019-11-20 | Genentech Inc | Formulaciones de anticuerpos de her2 subcutáneas |
CN116531511A (zh) | 2017-03-02 | 2023-08-04 | 豪夫迈·罗氏有限公司 | Her2阳性乳腺癌的辅助治疗 |
BE1025090B1 (fr) * | 2017-03-30 | 2018-10-29 | Univercells Sa | Procede et kit de purification de proteines |
KR102140693B1 (ko) * | 2017-04-14 | 2020-08-05 | 에이치케이이노엔 주식회사 | 양이온 교환 크로마토그래피를 이용한 유사항체 정제 방법 |
EP3615695A1 (fr) | 2017-04-24 | 2020-03-04 | Genentech, Inc. | Mutations erbb2/her2 dans le domaine transmembranaire ou juxtamembranaire |
KR102618831B1 (ko) | 2017-06-21 | 2023-12-28 | 세파론 엘엘씨 | 양이온 교환 크로마토그래피 세척 완충액 |
WO2019060718A1 (fr) * | 2017-09-22 | 2019-03-28 | Immunogen, Inc. | Séparation d'anticorps à chaîne triple légère à l'aide d'une chromatographie à échange de cations |
CN110272491B (zh) * | 2018-03-13 | 2023-01-24 | 江苏恒瑞医药股份有限公司 | 一种抗pd-1抗体的纯化工艺 |
WO2019191416A1 (fr) * | 2018-03-29 | 2019-10-03 | Bristol-Myers Squibb Company | Procédés de purification d'anticorps monoclonaux monomères |
US11612885B2 (en) * | 2018-05-08 | 2023-03-28 | Waters Technologies Corporation | Methods, compositions and kits useful for pH gradient cation exchange chromatography |
BR112021003420A2 (pt) | 2018-08-31 | 2021-05-18 | Genzyme Corporation | resina cromatográfica estéril e uso da mesma em processos de manufatura |
EP3643322A1 (fr) * | 2018-10-26 | 2020-04-29 | Mabion SA | Formulation de ligand anti cd20 à faible agrégat |
CN109320611B (zh) * | 2018-10-31 | 2022-06-03 | 鼎康(武汉)生物医药有限公司 | 一种人鼠嵌合单克隆抗体生物类似药的纯化方法 |
CN112206327A (zh) * | 2019-07-12 | 2021-01-12 | 上海药明生物技术有限公司 | 一种抗体偶联药物的制备及其高通量筛选方法 |
JP2023500790A (ja) * | 2019-10-14 | 2023-01-11 | ピアス・バイオテクノロジー・インコーポレイテッド | ペプチド精製配合物および方法 |
CN112830972A (zh) * | 2019-11-25 | 2021-05-25 | 中山康方生物医药有限公司 | 抗pd-1-抗vegfa的双特异性抗体、其药物组合物及其用途 |
KR102153258B1 (ko) * | 2020-02-21 | 2020-09-07 | 프레스티지바이오로직스 주식회사 | 베바시주맙 정제의 최적화된 방법 |
US11416468B2 (en) * | 2020-07-21 | 2022-08-16 | International Business Machines Corporation | Active-active system index management |
CN114591438B (zh) * | 2022-04-25 | 2023-12-05 | 达石药业(广东)有限公司 | 一种采用阳离子交换层析法纯化双特异性抗体的方法 |
WO2024090489A1 (fr) * | 2022-10-26 | 2024-05-02 | 日本メジフィジックス株式会社 | Procédé de production de composition pharmaceutique radioactive |
CN115850493B (zh) * | 2022-11-08 | 2024-03-12 | 江苏耀海生物制药有限公司 | 一种二价纳米抗体Cablivi的分离纯化方法 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999057134A1 (fr) * | 1998-05-06 | 1999-11-11 | Genentech, Inc. | Purification de proteines par chromatographie par echange d'ions |
WO2002096457A2 (fr) * | 2001-05-31 | 2002-12-05 | Novartis Ag | Formulations liquides stable s |
WO2004001007A2 (fr) * | 2002-06-21 | 2003-12-31 | Idec Pharmaceuticals Corporation | Preparations tamponnees permettant de concentrer des anticorps et procedes pour les utiliser |
WO2004024866A2 (fr) * | 2002-09-11 | 2004-03-25 | Genentech, Inc. | Purification de proteines |
WO2005066139A2 (fr) * | 2004-01-08 | 2005-07-21 | Millennium Pharmaceuticals, Inc. | 2-(amino-substituees)-4-aryl pyramidines et composes associes utiles dans le traitement de maladies inflammatoires |
WO2005115453A2 (fr) * | 2004-04-16 | 2005-12-08 | Genentech, Inc. | Traitement de troubles |
WO2006069403A2 (fr) * | 2004-12-22 | 2006-06-29 | Genentech, Inc. | Procedes pour la production d'une pluralite de proteines transmembranaires solubles |
WO2007028154A2 (fr) * | 2005-09-02 | 2007-03-08 | Northwestern University | Medicaments arsenicaux encapsules |
Family Cites Families (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
US4515893A (en) | 1979-04-26 | 1985-05-07 | Ortho Pharmaceutical Corporation | Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells |
GB2070818A (en) | 1980-02-04 | 1981-09-09 | Philips Electronic Associated | Regulated power supply for an image intensifier |
WO1984002129A1 (fr) | 1982-11-22 | 1984-06-07 | Takeda Chemical Industries Ltd | Proteine de l'interferon immun humain et son procede de preparation |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US6054561A (en) * | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
US4753894A (en) | 1984-02-08 | 1988-06-28 | Cetus Corporation | Monoclonal anti-human breast cancer antibodies |
US5169774A (en) | 1984-02-08 | 1992-12-08 | Cetus Oncology Corporation | Monoclonal anti-human breast cancer antibodies |
WO1986002068A1 (fr) | 1984-09-26 | 1986-04-10 | Takeda Chemical Industries, Ltd. | Separation mutuelle de proteines |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
US5196323A (en) | 1985-04-27 | 1993-03-23 | Boehringer Ingelheim International Gmbh | Process for preparing and purifying alpha-interferon |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US5525338A (en) | 1992-08-21 | 1996-06-11 | Immunomedics, Inc. | Detection and therapy of lesions with biotin/avidin conjugates |
US5091178A (en) | 1986-02-21 | 1992-02-25 | Oncogen | Tumor therapy with biologically active anti-tumor antibodies |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
CA1283072C (fr) | 1986-12-01 | 1991-04-16 | Timothy Durance | Procede d'isolement et de separation du lysozyme et de l'avidine du blanc d'oeuf |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US5451662A (en) | 1987-10-23 | 1995-09-19 | Schering Corporation | Method of purifying protein |
US5118796A (en) | 1987-12-09 | 1992-06-02 | Centocor, Incorporated | Efficient large-scale purification of immunoglobulins and derivatives |
US5091313A (en) | 1988-08-05 | 1992-02-25 | Tanox Biosystems, Inc. | Antigenic epitopes of IgE present on B cell but not basophil surface |
JP3040121B2 (ja) * | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
IT1219874B (it) | 1988-03-18 | 1990-05-24 | Fidia Farmaceutici | Utilizzazione del fattore di crescita nervoso umano e sue composizioni farmaceutiche |
US5115101A (en) | 1988-06-08 | 1992-05-19 | Miles Inc. | Removal of protein A from antibody preparations |
EP0420937B1 (fr) | 1988-06-21 | 1994-11-09 | Genentech, Inc. | Compositions therapeutiques pour le traitement de l'infarctus du myocarde |
EP0435911B1 (fr) | 1988-09-23 | 1996-03-13 | Cetus Oncology Corporation | Milieu de culture de cellules pour l'amelioration de la croissance des cellules, de la longivite de la culture et de l'expression du produit |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
EP0402226A1 (fr) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Vecteurs de transformation de la levure yarrowia |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5112951A (en) | 1989-07-28 | 1992-05-12 | Hybritech Incorporated | Separation of anti-metal chelate antibodies |
US5110913A (en) | 1990-05-25 | 1992-05-05 | Miles Inc. | Antibody purification method |
EP0467466A1 (fr) * | 1990-07-16 | 1992-01-22 | Eastman Kodak Company | Méthode de purification de conjugués immunoréactifs de thyroxine marquée |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
ES2193136T3 (es) | 1991-08-14 | 2003-11-01 | Genentech Inc | Variantes de inmunoglubina para receptores especificos de fc epsilon. |
WO1993006217A1 (fr) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION DANS L'E. COLI DE FRAGMENTS D'ANTICORPS POSSEDANT AU MOINS UNE CYSTEINE PRESENTE SOUS FORME D'UN THIOL LIBRE, ET LEUR UTILISATION DANS LA PRODUCTION D'ANTICORPS BIFONCTIONNELS F(ab')¿2? |
ES2241710T3 (es) | 1991-11-25 | 2005-11-01 | Enzon, Inc. | Procedimiento para producir proteinas multivalentes de union a antigeno. |
JPH05202098A (ja) | 1992-01-29 | 1993-08-10 | Snow Brand Milk Prod Co Ltd | 乳質原料から生理活性物質の製造法 |
EP0625200B1 (fr) | 1992-02-06 | 2005-05-11 | Chiron Corporation | Proteine de liaison biosynthetique pour marqueur de cancer |
US5279823A (en) * | 1992-06-08 | 1994-01-18 | Genentech, Inc. | Purified forms of DNASE |
MX9305070A (es) | 1992-08-21 | 1994-04-29 | Genentech Inc | Compocicion farmaceutica que contiene un antagonista de lfa-1 para el tratamiento de transtornos o desordenes mediados por el lfa-1 |
ATE196606T1 (de) | 1992-11-13 | 2000-10-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
ATE157455T1 (de) | 1993-12-10 | 1997-09-15 | Genentech Inc | Methoden zur diagnose von allergie und prüfung anti-allergischer therapeutika |
EP0739214B1 (fr) | 1994-01-18 | 1998-03-18 | Genentech, Inc. | PROCEDE DE TRAITEMENT DE LA PARASITOSE A L'AIDE D'ANTAGONISTES DE L'IgE |
US5429746A (en) | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
EP0749488A1 (fr) | 1994-03-03 | 1996-12-27 | Genentech, Inc. | Anticorps monoclonaux anti-il-8 pour le traitement des troubles |
US5534615A (en) | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5714583A (en) | 1995-06-07 | 1998-02-03 | Genetics Institute, Inc. | Factor IX purification methods |
AU6267896A (en) | 1995-06-07 | 1996-12-30 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth oftumors |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
DK0877626T3 (da) | 1996-01-23 | 2002-12-30 | Univ Vermont | Anti-CD18 antistoffer til anvendelse mod slagtilfælde |
US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
CZ300296B6 (cs) | 1996-11-15 | 2009-04-15 | Genentech, Inc. | Zpusob izolace rekombinantního lidského neurotrofinu, neurotrofinový prostredek a zpusob cištení neurotrofinu |
DK1516629T3 (da) | 1996-11-27 | 2013-06-03 | Genentech Inc | Humaniseret anti-CD-11a antibodies |
PT950067E (pt) | 1996-11-27 | 2007-12-06 | Genentech Inc | Purificação por afinidade de um polipéptido numa matriz de proteína a. |
US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
EP0971959B1 (fr) | 1997-04-07 | 2005-12-28 | Genentech, Inc. | Anticorps humanises et methode permettant de les produire |
AU743758B2 (en) | 1997-04-07 | 2002-02-07 | Genentech Inc. | Anti-VEGF antibodies |
ES2293682T5 (es) | 1997-05-15 | 2011-11-17 | Genentech, Inc. | Anticuerpo anti-apo2. |
US5994511A (en) | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
JP2002517406A (ja) | 1998-06-01 | 2002-06-18 | ジェネンテック・インコーポレーテッド | イオン交換クロマトグラフィーの使用による、凝集体からのタンパク質モノマーの分離 |
HU228076B1 (en) | 1998-06-09 | 2012-10-29 | Csl Behring Ag | Process for producing immunoglobulins for intravenous administration and other immunoglobulin products |
ES2329437T3 (es) | 1999-06-25 | 2009-11-26 | Genentech, Inc. | Anticuerpos anti-erbb2 humanizados y tratamiento con anticuerpos anti-erbb2. |
BR0015224A (pt) | 1999-10-29 | 2002-07-09 | Genentech Inc | Anticorpo anti-antìgeno de célula estaminal prostática (psca) isolado, anticorpo monoclonal anti-psca, ácido nucleico isolado, vetor de expressão, célula, célula hospedeira, método de produção de anticorpo, composição método in vitro para matar uma célula cancerosa que expresse psca, uso de uma anticorpo monoclonal anti-psca e artigo industrializado |
UA83458C2 (uk) | 2000-09-18 | 2008-07-25 | Байоджен Айдек Ма Інк. | Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf) |
US6417355B1 (en) | 2001-04-11 | 2002-07-09 | The United States Of America As Represented By The Secretary Of The Navy | Geminal-dinitro-1-5 diazocine derivatives |
US7321026B2 (en) | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
US6770027B2 (en) * | 2001-10-05 | 2004-08-03 | Scimed Life Systems, Inc. | Robotic endoscope with wireless interface |
AU2002351495A1 (en) | 2001-10-17 | 2003-04-28 | Human Genome Sciences, Inc. | Neutrokine-alpha and neutrokine-alpha splice variant |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
CA2476166C (fr) | 2002-02-14 | 2011-11-15 | Immunomedics, Inc. | Anticorps anti-cd20 et proteines hybrides desdits anticorps, et methodes d'utilisation |
ES2744275T3 (es) | 2002-10-17 | 2020-02-24 | Genmab As | Anticuerpos monoclonales humanos contra CD20 para su uso en el tratamiento de esclerosis múltiple |
AU2003287131B2 (en) | 2002-12-13 | 2008-07-24 | Mitra Medical Technology Ab | Antilymphoma targeting agents with effector and affinity functions linked by a trifunctional reagent |
SI1572744T1 (sl) | 2002-12-16 | 2010-09-30 | Genentech Inc | Imunoglobulinske variante in njihove uporabe |
BR0317896A (pt) | 2002-12-31 | 2005-12-06 | Altus Pharmaceuticals Inc | Complexos de cristais de proteìna e polìmeros iÈnicos |
EP1614693A4 (fr) * | 2003-03-31 | 2006-07-19 | Kirin Brewery | Purification d'un anticorps monoclonal humain et d'un anticorps polyclonal humain |
AU2004252067B2 (en) | 2003-05-09 | 2012-04-12 | Duke University | CD20-specific antibodies and methods of employing same |
AR044388A1 (es) | 2003-05-20 | 2005-09-07 | Applied Molecular Evolution | Moleculas de union a cd20 |
WO2005014618A2 (fr) | 2003-08-08 | 2005-02-17 | Immunomedics, Inc. | Anticorps bispecifiques pour induire l'apoptose de cellules tumorales et malades |
US8147832B2 (en) | 2003-08-14 | 2012-04-03 | Merck Patent Gmbh | CD20-binding polypeptide compositions and methods |
KR100524074B1 (ko) | 2003-10-01 | 2005-10-26 | 삼성전자주식회사 | 베젤 구조를 가지는 전자기기 |
CN101022829A (zh) * | 2004-04-16 | 2007-08-22 | 健泰科生物技术公司 | 用抗cd20抗体治疗多软骨炎和多发性单神经炎 |
CN104610422A (zh) * | 2005-03-11 | 2015-05-13 | 惠氏公司 | 弱分配层析的方法 |
AU2006259298B2 (en) * | 2005-06-17 | 2012-06-14 | Wyeth Llc | Methods of purifying Fc region containing proteins |
AU2007227700A1 (en) * | 2006-03-20 | 2007-09-27 | Medarex, Inc. | Protein purification |
EP2004689A4 (fr) * | 2006-04-05 | 2010-06-02 | Abbott Biotech Ltd | Purification d'anticorps |
ES2755386T5 (es) * | 2006-08-28 | 2023-04-05 | Ares Trading Sa | Proceso para la purificación de proteínas que contienen fragmentos Fc |
US8620738B2 (en) | 2006-08-31 | 2013-12-31 | Visa U.S.A. Inc | Loyalty program incentive determination |
AU2008232902B2 (en) * | 2007-03-30 | 2013-10-03 | Medlmmune, Llc | Antibody formulation |
PL2840090T3 (pl) | 2007-10-30 | 2018-07-31 | Genentech, Inc. | Oczyszczanie przeciwciał za pomocą chromatografii kationowymiennej |
WO2015198451A1 (fr) | 2014-06-26 | 2015-12-30 | 楽天株式会社 | Dispositif, procédé et programme informatiques |
-
2008
- 2008-10-29 PL PL14189095T patent/PL2840090T3/pl unknown
- 2008-10-29 JP JP2010532193A patent/JP5237382B2/ja active Active
- 2008-10-29 ES ES08844379.1T patent/ES2533266T5/es active Active
- 2008-10-29 HU HUE12189190A patent/HUE027668T2/en unknown
- 2008-10-29 HU HUE08844379A patent/HUE024877T2/en unknown
- 2008-10-29 TW TW103117553A patent/TWI554517B/zh active
- 2008-10-29 EP EP18151178.3A patent/EP3441402A1/fr not_active Withdrawn
- 2008-10-29 DK DK12189190.7T patent/DK2565206T3/en active
- 2008-10-29 RS RS20150156A patent/RS53850B2/sr unknown
- 2008-10-29 CA CA2703279A patent/CA2703279C/fr active Active
- 2008-10-29 ME MEP-2015-34A patent/ME02101B/me unknown
- 2008-10-29 TW TW097141614A patent/TWI448330B/zh active
- 2008-10-29 SG SG10201401690XA patent/SG10201401690XA/en unknown
- 2008-10-29 PT PT88443791T patent/PT2215117E/pt unknown
- 2008-10-29 EP EP14189095.4A patent/EP2840090B1/fr active Active
- 2008-10-29 US US12/260,623 patent/US20090148435A1/en not_active Abandoned
- 2008-10-29 CN CN201310495290.7A patent/CN103554215B/zh active Active
- 2008-10-29 MX MX2010004740A patent/MX2010004740A/es active IP Right Grant
- 2008-10-29 ES ES12189190.7T patent/ES2572958T3/es active Active
- 2008-10-29 HU HUE14189095A patent/HUE037409T2/hu unknown
- 2008-10-29 EP EP12189190.7A patent/EP2565206B1/fr active Active
- 2008-10-29 NZ NZ584839A patent/NZ584839A/en unknown
- 2008-10-29 WO PCT/US2008/081516 patent/WO2009058812A1/fr active Application Filing
- 2008-10-29 SI SI200831634A patent/SI2565206T1/sl unknown
- 2008-10-29 DK DK14189095.4T patent/DK2840090T3/en active
- 2008-10-29 AR ARP080104725A patent/AR069097A1/es active IP Right Grant
- 2008-10-29 KR KR1020107011765A patent/KR101241486B1/ko active IP Right Grant
- 2008-10-29 DK DK08844379.1T patent/DK2215117T4/en active
- 2008-10-29 EP EP08844379.1A patent/EP2215117B2/fr active Active
- 2008-10-29 KR KR1020147036127A patent/KR20150008503A/ko not_active Application Discontinuation
- 2008-10-29 PL PL08844379T patent/PL2215117T5/pl unknown
- 2008-10-29 BR BRPI0817182 patent/BRPI0817182A2/pt not_active Application Discontinuation
- 2008-10-29 ES ES14189095.4T patent/ES2666170T3/es active Active
- 2008-10-29 CN CN200880119331XA patent/CN101889025B/zh active Active
- 2008-10-29 PE PE2008001848A patent/PE20091434A1/es active IP Right Grant
- 2008-10-29 CL CL2008003218A patent/CL2008003218A1/es unknown
- 2008-10-29 SG SG2011073087A patent/SG175597A1/en unknown
- 2008-10-29 AU AU2008318865A patent/AU2008318865B2/en active Active
- 2008-10-29 PL PL12189190T patent/PL2565206T3/pl unknown
- 2008-10-29 RU RU2010121816/10A patent/RU2498991C2/ru active
- 2008-10-29 CN CN201510941252.9A patent/CN105315323A/zh active Pending
- 2008-10-29 KR KR1020127028627A patent/KR20140015166A/ko not_active Application Discontinuation
- 2008-10-29 SI SI200831945T patent/SI2840090T1/en unknown
- 2008-10-29 SI SI200831381T patent/SI2215117T2/en unknown
-
2010
- 2010-04-22 ZA ZA2010/02850A patent/ZA201002850B/en unknown
- 2010-04-25 IL IL205310A patent/IL205310A0/en unknown
- 2010-05-21 CO CO10061141A patent/CO6280422A2/es active IP Right Grant
- 2010-10-28 HK HK13109765.9A patent/HK1182401A1/zh unknown
- 2010-10-28 HK HK10110121.9A patent/HK1143821A1/xx active IP Right Maintenance
-
2011
- 2011-03-23 ZA ZA2011/02169A patent/ZA201102169B/en unknown
-
2013
- 2013-03-21 JP JP2013059102A patent/JP2013173747A/ja not_active Withdrawn
- 2013-06-03 PH PH12013501128A patent/PH12013501128A1/en unknown
-
2014
- 2014-09-30 IL IL234902A patent/IL234902A0/en unknown
- 2014-09-30 IL IL234901A patent/IL234901A0/en unknown
- 2014-11-03 US US14/531,880 patent/US9896478B2/en active Active
-
2015
- 2015-02-19 JP JP2015030880A patent/JP5885864B2/ja active Active
- 2015-02-19 JP JP2015030881A patent/JP2015155406A/ja not_active Withdrawn
- 2015-03-12 HR HRP20150282TT patent/HRP20150282T4/hr unknown
- 2015-03-19 CY CY20151100275T patent/CY1116129T1/el unknown
- 2015-06-18 IL IL239495A patent/IL239495B/en not_active IP Right Cessation
- 2015-07-28 HK HK15107237.1A patent/HK1206753A1/xx unknown
-
2016
- 2016-07-12 JP JP2016137986A patent/JP2017019790A/ja active Pending
- 2016-08-08 HK HK16109407.0A patent/HK1221234A1/zh unknown
-
2017
- 2017-12-21 US US15/850,885 patent/US20180118781A1/en not_active Abandoned
-
2018
- 2018-03-09 AR ARP180100555A patent/AR111171A2/es unknown
- 2018-06-18 HR HRP20180943TT patent/HRP20180943T1/hr unknown
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999057134A1 (fr) * | 1998-05-06 | 1999-11-11 | Genentech, Inc. | Purification de proteines par chromatographie par echange d'ions |
US6339142B1 (en) * | 1998-05-06 | 2002-01-15 | Genentech, Inc. | Protein purification |
WO2002096457A2 (fr) * | 2001-05-31 | 2002-12-05 | Novartis Ag | Formulations liquides stable s |
WO2004001007A2 (fr) * | 2002-06-21 | 2003-12-31 | Idec Pharmaceuticals Corporation | Preparations tamponnees permettant de concentrer des anticorps et procedes pour les utiliser |
WO2004024866A2 (fr) * | 2002-09-11 | 2004-03-25 | Genentech, Inc. | Purification de proteines |
WO2005066139A2 (fr) * | 2004-01-08 | 2005-07-21 | Millennium Pharmaceuticals, Inc. | 2-(amino-substituees)-4-aryl pyramidines et composes associes utiles dans le traitement de maladies inflammatoires |
WO2005115453A2 (fr) * | 2004-04-16 | 2005-12-08 | Genentech, Inc. | Traitement de troubles |
WO2006069403A2 (fr) * | 2004-12-22 | 2006-06-29 | Genentech, Inc. | Procedes pour la production d'une pluralite de proteines transmembranaires solubles |
WO2007028154A2 (fr) * | 2005-09-02 | 2007-03-08 | Northwestern University | Medicaments arsenicaux encapsules |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2565206A3 (fr) | Purification d'anticorps par chromatographie à échange de cations | |
WO2007109163A3 (fr) | Tampon de lavage et procédé d'utilisation correspondant | |
UA99262C2 (uk) | СПОСІБ ЗМЕНШЕННЯ КОНЦЕНТРАЦІЇ ВІЛЬНИХ Fc-ЧАСТИН В РІДИНІ, ЩО МІСТИТЬ Fc-ВМІСНИЙ БІЛОК | |
WO2008031020A3 (fr) | Solution de lavage contenant de l'arginine utilisée dans la purification de protéines par chromatographie d'affinité | |
WO2008087184A3 (fr) | Procédé pour la purification de protéines contenant fc | |
WO2011043604A3 (fr) | Électrode composite de désionisation capacitive sélective vis-à-vis des ions et procédé de fabrication d'un module | |
AR074015A1 (es) | Purificacion de proteinas acidas utilizando cromatografia de hidroxiapatita ceramica | |
WO2011090720A3 (fr) | Purification des protéines | |
MY157846A (en) | Process for the purification of fc-containing proteins | |
WO2011063195A3 (fr) | Purification de cytokines modifiées | |
MX2013013224A (es) | Procedimiento de purificacion de proteinas de bajo ph. | |
HK1125970A1 (en) | Process for the purification of recombinant alpha 1-antitrypsin involving a step of anion exchange chromatography | |
ATE468343T1 (de) | Verfahren zur reinigung von tacrolimus | |
TH104746B (th) | การทำให้บริสุทธิ์ของแอนตี้บอดี้โดยการโครมาโตกราฟีแบบแลกเปลี่ยนประจุบวก | |
TH104746A (th) | การทำให้บริสุทธิ์ของแอนตี้บอดี้โดยการโครมาโตกราฟีแบบแลกเปลี่ยนประจุบวก | |
UA27589U (en) | Method for adsorption purification of potable water | |
RU2012143225A (ru) | Способ выделения и очистки иммобилизованного фермента | |
UA4249U (uk) | Спосіб очищення стічних вод від прямих барвників | |
UA29227U (ru) | Состав сорбционного фильтра для очистки питьевой воды |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AC | Divisional application: reference to earlier application |
Ref document number: 2215117 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA MK RS |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 16/06 20060101AFI20130719BHEP Ipc: C07K 1/18 20060101ALI20130719BHEP Ipc: C07K 16/28 20060101ALI20130719BHEP Ipc: C07K 16/22 20060101ALI20130719BHEP |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA MK RS |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 16/28 20060101ALI20130927BHEP Ipc: C07K 16/06 20060101AFI20130927BHEP Ipc: C07K 16/22 20060101ALI20130927BHEP Ipc: C07K 1/18 20060101ALI20130927BHEP |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1182401 Country of ref document: HK |
|
17P | Request for examination filed |
Effective date: 20140422 |
|
RAX | Requested extension states of the european patent have changed |
Extension state: RS Payment date: 20140422 Extension state: MK Payment date: 20140422 Extension state: BA Payment date: 20140422 Extension state: AL Payment date: 20140422 |
|
RBV | Designated contracting states (corrected) |
Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
17Q | First examination report despatched |
Effective date: 20140519 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: O'CONNOR, DEBORAH ANN Inventor name: SAFTA, AURELIA Inventor name: SHARMA, MANDAKINI Inventor name: LEBRETON, BENEDICTE ANDREE |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 16/06 20060101AFI20150819BHEP Ipc: C07K 1/18 20060101ALI20150819BHEP Ipc: C07K 1/36 20060101ALI20150819BHEP Ipc: C07K 16/28 20060101ALI20150819BHEP |
|
INTG | Intention to grant announced |
Effective date: 20150921 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AC | Divisional application: reference to earlier application |
Ref document number: 2215117 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA MK RS |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 785314 Country of ref document: AT Kind code of ref document: T Effective date: 20160415 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: F. HOFFMANN-LA ROCHE AG, CH |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602008043260 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2572958 Country of ref document: ES Kind code of ref document: T3 Effective date: 20160603 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 Effective date: 20160602 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160630 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160330 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160330 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160701 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160330 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160330 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 9 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160330 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160730 |
|
REG | Reference to a national code |
Ref country code: HU Ref legal event code: AG4A Ref document number: E027668 Country of ref document: HU |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160801 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160330 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160330 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602008043260 Country of ref document: DE |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20170103 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: UEP Ref document number: 785314 Country of ref document: AT Kind code of ref document: T Effective date: 20160330 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1182401 Country of ref document: HK |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161029 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 10 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160330 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160330 Ref country code: MT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161031 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160330 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20230922 Year of fee payment: 16 Ref country code: IT Payment date: 20230920 Year of fee payment: 16 Ref country code: IE Payment date: 20230921 Year of fee payment: 16 Ref country code: GB Payment date: 20230920 Year of fee payment: 16 Ref country code: CZ Payment date: 20230926 Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20230922 Year of fee payment: 16 Ref country code: PL Payment date: 20230927 Year of fee payment: 16 Ref country code: FR Payment date: 20230920 Year of fee payment: 16 Ref country code: DK Payment date: 20230920 Year of fee payment: 16 Ref country code: BE Payment date: 20230920 Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20231102 Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: TR Payment date: 20231002 Year of fee payment: 16 Ref country code: SI Payment date: 20231006 Year of fee payment: 16 Ref country code: HU Payment date: 20231004 Year of fee payment: 16 Ref country code: DE Payment date: 20230920 Year of fee payment: 16 Ref country code: CH Payment date: 20231102 Year of fee payment: 16 Ref country code: AT Payment date: 20230921 Year of fee payment: 16 |